Matches in Wikidata for { <http://www.wikidata.org/entity/Q96612030> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- Q96612030 description "article scientifique publié en 2020" @default.
- Q96612030 description "artículu científicu espublizáu en xunu de 2020" @default.
- Q96612030 description "scientific article published on 20 June 2020" @default.
- Q96612030 description "wetenschappelijk artikel" @default.
- Q96612030 description "наукова стаття, опублікована 20 червня 2020" @default.
- Q96612030 description "գիտական հոդված հրատարակված 2020 թվականի հունիսի 20-ին" @default.
- Q96612030 name "Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT trial eligibility criteria" @default.
- Q96612030 name "Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT trial eligibility criteria" @default.
- Q96612030 type Item @default.
- Q96612030 label "Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT trial eligibility criteria" @default.
- Q96612030 label "Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT trial eligibility criteria" @default.
- Q96612030 prefLabel "Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT trial eligibility criteria" @default.
- Q96612030 prefLabel "Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT trial eligibility criteria" @default.
- Q96612030 P1433 Q96612030-D09BDA49-E4EB-4E15-838C-3E19D69A38FE @default.
- Q96612030 P1476 Q96612030-19D0C8AE-DE17-4C73-9367-7DD680447514 @default.
- Q96612030 P2093 Q96612030-2864FEFD-87A2-4FF6-8B72-0A6DA9673B48 @default.
- Q96612030 P2093 Q96612030-2DDA7D32-6853-42DA-AE7D-00CAF0EF2EB4 @default.
- Q96612030 P2093 Q96612030-2EE5F1D4-317D-4C44-9DC8-793F7BFFB8EA @default.
- Q96612030 P2093 Q96612030-3F9129E7-0A9C-4514-9C02-2D336C049AC9 @default.
- Q96612030 P2093 Q96612030-421B2249-69DA-49C1-89A3-78B5F8CBB037 @default.
- Q96612030 P2093 Q96612030-5715BBC3-5FD6-4AB7-A20A-D56C52ABB2C8 @default.
- Q96612030 P2093 Q96612030-88472286-F5BE-424D-BD27-ABDA749A4C62 @default.
- Q96612030 P2093 Q96612030-8A9EDF20-C32C-48C0-B448-8F9D4B5701A2 @default.
- Q96612030 P2093 Q96612030-8BDB3539-5340-4EFD-A967-B058F49940E2 @default.
- Q96612030 P2093 Q96612030-8C400B3C-7B13-428C-A6BF-850226D821B4 @default.
- Q96612030 P2093 Q96612030-93AF23A0-2C52-4434-A4E6-027C99451FF3 @default.
- Q96612030 P2093 Q96612030-962C3ABD-D64E-4D20-B1D6-90A906299A2F @default.
- Q96612030 P2093 Q96612030-97BD8B35-E622-4136-9E68-207CCD2E13DA @default.
- Q96612030 P2093 Q96612030-AC58D55C-966C-4665-B291-C69CB431C3DD @default.
- Q96612030 P2093 Q96612030-ACA0AD9F-B04C-4B31-92C3-C714D93779C2 @default.
- Q96612030 P2093 Q96612030-BDA07095-B50F-44EC-9929-CD3E54B2A6B5 @default.
- Q96612030 P2093 Q96612030-BFB3A05C-B0B4-4552-BBBE-D272CFE42D77 @default.
- Q96612030 P2093 Q96612030-C580AD94-1C15-4EC7-A595-24E61C8B8898 @default.
- Q96612030 P2093 Q96612030-F23E99B3-5A4E-43EB-A334-30231ED19B67 @default.
- Q96612030 P2093 Q96612030-FCE74083-FB38-4ABE-BC1C-9940A8C70FBB @default.
- Q96612030 P2093 Q96612030-FDDB4921-DE41-4056-A2A6-47A28FC6C5CD @default.
- Q96612030 P31 Q96612030-DC51AF40-168A-4E11-8F29-AEE73C73C3FF @default.
- Q96612030 P356 Q96612030-7457BF15-ADEF-470E-A442-08ED15FE3E25 @default.
- Q96612030 P50 Q96612030-4C6BAC8F-DE46-4178-837B-C5B9794F1195 @default.
- Q96612030 P50 Q96612030-B439DF34-FAB8-4F6D-8B6B-610A13717DB6 @default.
- Q96612030 P50 Q96612030-E8489C3C-2E1A-4EBA-AD37-0C8BAD078B94 @default.
- Q96612030 P50 Q96612030-FC6BDAC5-4B63-424E-9DA6-50A77EBCA04A @default.
- Q96612030 P577 Q96612030-8054C714-D148-4549-A2FB-22056575F955 @default.
- Q96612030 P698 Q96612030-496104BE-0C47-4AD0-969A-70EF27999948 @default.
- Q96612030 P921 Q96612030-970EAF66-1BC1-4E1F-8CA3-412290465F05 @default.
- Q96612030 P356 HEPR.13511 @default.
- Q96612030 P698 32562334 @default.
- Q96612030 P1433 Q15752035 @default.
- Q96612030 P1476 "Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT trial eligibility criteria" @default.
- Q96612030 P2093 "Akihisa Nakamura" @default.
- Q96612030 P2093 "Akinobu Taketomi" @default.
- Q96612030 P2093 "Akiyoshi Saga" @default.
- Q96612030 P2093 "Jun Ito" @default.
- Q96612030 P2093 "Katsumi Terasita" @default.
- Q96612030 P2093 "Kazuharu Suzuki" @default.
- Q96612030 P2093 "Ken Furuya" @default.
- Q96612030 P2093 "Koji Ogawa" @default.
- Q96612030 P2093 "Machiko Umemura" @default.
- Q96612030 P2093 "Masato Nakai" @default.
- Q96612030 P2093 "Masatsugu Ohara" @default.
- Q96612030 P2093 "Mitsuteru Natsuizaka" @default.
- Q96612030 P2093 "Naoya Sakamoto" @default.
- Q96612030 P2093 "Takashi Meguro" @default.
- Q96612030 P2093 "Taku Shigesawa" @default.
- Q96612030 P2093 "Takuto Miyagishima" @default.
- Q96612030 P2093 "Takuya Sho" @default.
- Q96612030 P2093 "Tomoe Kobayashi" @default.
- Q96612030 P2093 "Tomofumi Takagi" @default.
- Q96612030 P2093 "Toshiya Kamiyama" @default.
- Q96612030 P2093 "Yoshiya Yamamoto" @default.
- Q96612030 P31 Q13442814 @default.
- Q96612030 P356 "10.1111/HEPR.13511" @default.
- Q96612030 P50 Q87747149 @default.
- Q96612030 P50 Q88350056 @default.
- Q96612030 P50 Q89535094 @default.
- Q96612030 P50 Q96612029 @default.
- Q96612030 P577 "2020-06-20T00:00:00Z" @default.
- Q96612030 P698 "32562334" @default.
- Q96612030 P921 Q114840239 @default.